{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:40:22Z","timestamp":1787499622612,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1038\/s41401-020-0477-4","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T03:02:54Z","timestamp":1596510174000},"page":"744-754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Oridonin ameliorates inflammation-induced bone loss in mice via suppressing DC-STAMP expression"],"prefix":"10.1038","volume":"42","author":[{"given":"Bin-hua","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-hui","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-de","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-huang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-hong","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-bao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"477_CR1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.tcb.2009.07.005","volume":"19","author":"L Helming","year":"2009","unstructured":"Helming L, Gordon S. Molecular mediators of macrophage fusion. Trends Cell Biol. 2009;19:514\u201322.","journal-title":"Trends Cell Biol"},{"key":"477_CR2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00418-018-1636-2","volume":"149","author":"T Ono","year":"2018","unstructured":"Ono T, Nakashima T. Recent advances in osteoclast biology. Histochem Cell Biol. 2018;149:325\u201341.","journal-title":"Histochem Cell Biol"},{"key":"477_CR3","doi-asserted-by":"crossref","first-page":"13984","DOI":"10.1074\/jbc.M213067200","volume":"279","author":"H Hirotani","year":"2004","unstructured":"Hirotani H, Tuohy NA, Woo JT, Stern PH, Clipstone NA. The calcineurin\/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem. 2004;279:13984\u201392.","journal-title":"J Biol Chem"},{"key":"477_CR4","doi-asserted-by":"crossref","first-page":"26475","DOI":"10.1074\/jbc.M313973200","volume":"279","author":"K Matsuo","year":"2004","unstructured":"Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem. 2004;279:26475\u201380.","journal-title":"J Biol Chem"},{"key":"477_CR5","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.4049\/jimmunol.177.4.2384","volume":"177","author":"F Ikeda","year":"2006","unstructured":"Ikeda F, Nishimura R, Matsubara T, Hata K, Reddy SV, Yoneda T. Activation of NFAT signal in vivo leads to osteopenia associated with increased osteoclastogenesis and bone-resorbing activity. J Immunol. 2006;177:2384\u201390.","journal-title":"J Immunol"},{"key":"477_CR6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1196\/annals.1402.071","volume":"1116","author":"H Takayanagi","year":"2007","unstructured":"Takayanagi H. The role of NFAT in osteoclast formation. Ann N Y Acad Sci. 2007;1116:227\u201337.","journal-title":"Ann N Y Acad Sci"},{"key":"477_CR7","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s00198-005-2023-0","volume":"16","author":"J Fechtenbaum","year":"2005","unstructured":"Fechtenbaum J, Cropet C, Kolta S, Horlait S, Orcel P, Roux C. The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women. Osteoporos Int. 2005;16:2175\u20139.","journal-title":"Osteoporos Int"},{"key":"477_CR8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/jbmr.1885","volume":"28","author":"BF Boyce","year":"2013","unstructured":"Boyce BF. Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res. 2013;28:711\u201322.","journal-title":"J Bone Miner Res"},{"key":"477_CR9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13018-014-0056-9","volume":"9","author":"T Li","year":"2014","unstructured":"Li T, Wu SM, Xu ZY, Ou-Yang S. Rabbiteye blueberry prevents osteoporosis in ovariectomized rats. J Orthop Surg Res. 2014;9:56.","journal-title":"J Orthop Surg Res"},{"key":"477_CR10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/BOR.0000000000000365","volume":"29","author":"JA Cauley","year":"2017","unstructured":"Cauley JA. Osteoporosis: fracture epidemiology update 2016. Curr Opin Rheumatol. 2017;29:150\u20136.","journal-title":"Curr Opin Rheumatol"},{"key":"477_CR11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-065X.2009.00821.x","volume":"231","author":"T Negishi-Koga","year":"2009","unstructured":"Negishi-Koga T, Takayanagi H. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev. 2009;231:241\u201356.","journal-title":"Immunol Rev"},{"key":"477_CR12","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/jbmr.1973","volume":"28","author":"J Kim","year":"2013","unstructured":"Kim J, Yang J, Park OJ, Kang SS, Kim WS, Kurokawa K, et al. Lipoproteins are an important bacterial component responsible for bone destruction through the induction of osteoclast differentiation and activation. J Bone Miner Res. 2013;28:2381\u201391.","journal-title":"J Bone Miner Res"},{"key":"477_CR13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1084\/jem.20050645","volume":"202","author":"M Yagi","year":"2005","unstructured":"Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med. 2005;202:345\u201351.","journal-title":"J Exp Med"},{"key":"477_CR14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/s10165-006-0524-0","volume":"16","author":"T Miyamoto","year":"2006","unstructured":"Miyamoto T. The dendritic cell-specific transmembrane protein DC-STAMP is essential for osteoclast fusion and osteoclast bone-resorbing activity. Mod Rheumatol. 2006;16:341\u20132.","journal-title":"Mod Rheumatol"},{"key":"477_CR15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jbmr.531","volume":"27","author":"YH Chiu","year":"2012","unstructured":"Chiu YH, Mensah KA, Schwarz EM, Ju Y, Takahata M, Feng C, et al. Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res. 2012;27:79\u201392.","journal-title":"J Bone Miner Res"},{"key":"477_CR16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1084\/jem.20040518","volume":"200","author":"T Kukita","year":"2004","unstructured":"Kukita T, Wada N, Kukita A, Kakimoto T, Sandra F, Toh K, et al. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med. 2004;200:941\u20136.","journal-title":"J Exp Med"},{"key":"477_CR17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phymed.2014.10.008","volume":"22","author":"JM Baek","year":"2015","unstructured":"Baek JM, Kim JY, Jung Y, Moon SH, Choi MK, Kim SH, et al. Mollugin from Rubea cordifolia suppresses receptor activator of nuclear factor-kappaB ligand-induced osteoclastogenesis and bone resorbing activity in vitro and prevents lipopolysaccharide-induced bone loss in vivo. Phytomedicine. 2015;22:27\u201335.","journal-title":"Phytomedicine"},{"key":"477_CR18","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/jcp.25389","volume":"231","author":"YH Chiu","year":"2016","unstructured":"Chiu YH, Ritchlin CT. DC-STAMP: a key regulator in osteoclast differentiation. J Cell Physiol. 2016;231:2402\u20137.","journal-title":"J Cell Physiol"},{"key":"477_CR19","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/jcp.25638","volume":"232","author":"YH Chiu","year":"2017","unstructured":"Chiu YH, Schwarz E, Li D, Xu Y, Sheu TR, Li J, et al. Dendritic cell-specific transmembrane protein (DC-STAMP) regulates osteoclast differentiation via the Ca2+ \/NFATc1 Axis. J Cell Physiol. 2017;232:2538\u201349.","journal-title":"J Cell Physiol"},{"key":"477_CR20","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.bbrc.2008.10.076","volume":"377","author":"R Iwasaki","year":"2008","unstructured":"Iwasaki R, Ninomiya K, Miyamoto K, Suzuki T, Sato Y, Kawana H, et al. Cell fusion in osteoclasts plays a critical role in controlling bone mass and osteoblastic activity. Biochem Biophys Res Commun. 2008;377:899\u2013904.","journal-title":"Biochem Biophys Res Commun"},{"key":"477_CR21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/0022034517690490","volume":"96","author":"W Wisitrasameewong","year":"2017","unstructured":"Wisitrasameewong W, Kajiya M, Movila A, Rittling S, Ishii T, Suzuki M, et al. DC-STAMP is an osteoclast fusogen engaged in periodontal bone resorption. J Dent Res. 2017;96:685\u201393.","journal-title":"J Dent Res"},{"key":"477_CR22","doi-asserted-by":"publisher","first-page":"1000127","DOI":"10.4172\/2329-8820.1000127","volume":"1","author":"YG Chiu","year":"2013","unstructured":"Chiu YG, Ritchlin CT. Characterization of DC-STAMP+ cells in human bone marrow. J Bone Marrow Res. 2013;1:1000127. https:\/\/doi.org\/10.4172\/2329-8820.1000127.","journal-title":"J Bone Marrow Res"},{"key":"477_CR23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40268-015-0102-z","volume":"15","author":"BA Owona","year":"2015","unstructured":"Owona BA, Schluesener HJ. Molecular insight in the multifunctional effects of oridonin. Drugs R D. 2015;15:233\u201344.","journal-title":"Drugs R D"},{"key":"477_CR24","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.3892\/or.2016.4654","volume":"35","author":"CM Ren","year":"2016","unstructured":"Ren CM, Li Y, Chen QZ, Zeng YH, Shao Y, Wu QX, et al. Oridonin inhibits the proliferation of human colon cancer cells by upregulating BMP7 to activate p38 MAPK. Oncol Rep. 2016;35:2691\u20138.","journal-title":"Oncol Rep"},{"key":"477_CR25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/CAD.0b013e3282f435b6","volume":"19","author":"T Rajkumar","year":"2008","unstructured":"Rajkumar T, Yamuna M. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line. Anticancer Drugs. 2008;19:257\u201365.","journal-title":"Anticancer Drugs"},{"key":"477_CR26","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3109\/10428194.2015.1061127","volume":"57","author":"ZZ Xu","year":"2016","unstructured":"Xu ZZ, Fu WB, Jin Z, Guo P, Wang WF, Li JM. Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma. Leuk Lymphoma. 2016;57:888\u201398.","journal-title":"Leuk Lymphoma"},{"key":"477_CR27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1142\/S0192415X13500134","volume":"41","author":"S Wang","year":"2013","unstructured":"Wang S, Zhong Z, Wan J, Tan W, Wu G, Chen M, et al. Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells. Am J Chin Med. 2013;41:177\u201396.","journal-title":"Am J Chin Med"},{"key":"477_CR28","volume":"9","author":"Y Lu","year":"2018","unstructured":"Lu Y, Sun Y, Zhu J, Yu L, Jiang X, Zhang J, et al. Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-gamma and inhibiting Nrf2 pathway. Cell Death Dis. 2018;9:15.","journal-title":"Cell Death Dis"},{"key":"477_CR29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/aps.2014.25","volume":"35","author":"FF Li","year":"2014","unstructured":"Li FF, Yi S, Wen L, He J, Yang LJ, Zhao J, et al. Oridonin induces NPM mutant protein translocation and apoptosis in NPM1c+ acute myeloid leukemia cells in vitro. Acta Pharmacol Sin. 2014;35:806\u201313.","journal-title":"Acta Pharmacol Sin"},{"key":"477_CR30","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/jbmr.3334","volume":"33","author":"Z Xie","year":"2018","unstructured":"Xie Z, Yu H, Sun X, Tang P, Jie Z, Chen S, et al. A novel diterpenoid suppresses osteoclastogenesis and promotes osteogenesis by inhibiting Ifrd1-mediated and IkappaBalpha-mediated p65 nuclear translocation. J Bone Miner Res. 2018;33:667\u201378.","journal-title":"J Bone Miner Res"},{"key":"477_CR31","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1177\/0022034518777973","volume":"97","author":"A Viniegra","year":"2018","unstructured":"Viniegra A, Goldberg H, Cil C, Fine N, Sheikh Z, Galli M, et al. Resolving macrophages counter osteolysis by anabolic actions on bone cells. J Dent Res. 2018;97:1160\u20139.","journal-title":"J Dent Res"},{"key":"477_CR32","volume":"9","author":"H He","year":"2018","unstructured":"He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. 2018;9:2550.","journal-title":"Nat Commun"},{"key":"477_CR33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bcp.2016.10.007","volume":"124","author":"X Zeng","year":"2017","unstructured":"Zeng X, Zhang Y, Wang S, Wang K, Tao L, Zou M, et al. Artesunate suppresses RANKL-induced osteoclastogenesis through inhibition of PLCgamma1-Ca2+-NFATc1 signaling pathway and prevents ovariectomy-induced bone loss. Biochem Pharmacol. 2017;124:57\u201368.","journal-title":"Biochem Pharmacol"},{"key":"477_CR34","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/jbmr.2771","volume":"31","author":"L Zhou","year":"2016","unstructured":"Zhou L, Liu Q, Yang M, Wang T, Yao J, Cheng J, et al. Dihydroartemisinin, an anti-malaria drug, suppresses estrogen deficiency-induced osteoporosis, osteoclast formation, and RANKL-induced signaling pathways. J Bone Miner Res. 2016;31:964\u201374.","journal-title":"J Bone Miner Res"},{"key":"477_CR35","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bone.2009.10.042","volume":"46","author":"HB Kwak","year":"2010","unstructured":"Kwak HB, Lee BK, Oh J, Yeon JT, Choi SW, Cho HJ, et al. Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression. Bone. 2010;46:724\u201331.","journal-title":"Bone"},{"key":"477_CR36","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.4049\/jimmunol.1003738","volume":"189","author":"JM Lee","year":"2012","unstructured":"Lee JM, Park H, Noh AL, Kang JH, Chen L, Zheng T, et al. 5-Lipoxygenase mediates RANKL-induced osteoclast formation via the cysteinyl leukotriene receptor 1. J Immunol. 2012;189:5284\u201392.","journal-title":"J Immunol"},{"key":"477_CR37","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/bph.12463","volume":"171","author":"ZJ Zhai","year":"2014","unstructured":"Zhai ZJ, Li HW, Liu GW, Qu XH, Tian B, Yan W, et al. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Br J Pharmacol. 2014;171:663\u201375.","journal-title":"Br J Pharmacol"},{"key":"477_CR38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bcp.2018.02.019","volume":"151","author":"HJ Park","year":"2018","unstructured":"Park HJ, Son HJ, Sul OJ, Suh JH, Choi HS. 4-Phenylbutyric acid protects against lipopolysaccharide-induced bone loss by modulating autophagy in osteoclasts. Biochem Pharmacol. 2018;151:9\u201317.","journal-title":"Biochem Pharmacol"},{"key":"477_CR39","first-page":"5743","volume":"9","author":"Y Yin","year":"2017","unstructured":"Yin Y, Tang L, Chen J, Lu X. MiR-30a attenuates osteoclastogenesis via targeting DC-STAMP-c-Fos-NFATc1 signaling. Am J Transl Res. 2017;9:5743\u201353.","journal-title":"Am J Transl Res"},{"key":"477_CR40","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.bbagrm.2014.08.002","volume":"1839","author":"C Dou","year":"2014","unstructured":"Dou C, Zhang C, Kang F, Yang X, Jiang H, Bai Y, et al. MiR-7b directly targets DC-STAMP causing suppression of NFATc1 and c-Fos signaling during osteoclast fusion and differentiation. Biochim Biophys Acta. 2014;1839:1084\u201396.","journal-title":"Biochim Biophys Acta"},{"key":"477_CR41","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1534-5807(02)00369-6","volume":"3","author":"H Takayanagi","year":"2002","unstructured":"Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3:889\u2013901.","journal-title":"Dev Cell"},{"key":"477_CR42","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1084\/jem.20051150","volume":"202","author":"M Asagiri","year":"2005","unstructured":"Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med. 2005;202:1261\u20139.","journal-title":"J Exp Med"},{"key":"477_CR43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nri2062","volume":"7","author":"H Takayanagi","year":"2007","unstructured":"Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7:292\u2013304.","journal-title":"Nat Rev Immunol"},{"key":"477_CR44","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","volume":"84","author":"KA Kennel","year":"2009","unstructured":"Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009;84:632\u20137. quiz 8","journal-title":"Mayo Clin Proc"},{"key":"477_CR45","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","volume":"27","author":"EB Andrews","year":"2012","unstructured":"Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012;27:2429\u201337.","journal-title":"J Bone Miner Res"},{"key":"477_CR46","doi-asserted-by":"crossref","first-page":"iv108","DOI":"10.1093\/rheumatology\/kex496","volume":"57","author":"Z Huang","year":"2018","unstructured":"Huang Z, Ding C, Li T, Yu SP. Current status and future prospects for disease modification in osteoarthritis. Rheumatology. 2018;57:iv108\u201323.","journal-title":"Rheumatology"},{"key":"477_CR47","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393:364\u201376.","journal-title":"Lancet"},{"key":"477_CR48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jb\/mvt049","volume":"154","author":"L Danks","year":"2013","unstructured":"Danks L, Takayanagi H. Immunology and bone. J Biochem. 2013;154:29\u201339.","journal-title":"J Biochem"},{"key":"477_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejr.2014.06.001","volume":"37","author":"S Fadda","year":"2015","unstructured":"Fadda S, Hamdy A, Abulkhair E, Mahmoud Elsify H, Mostafa A. Serum levels of osteoprotegerin and RANKL in patients with rheumatoid arthritis and their relation to bone mineral density and disease activity. Egypt Rheumatologist. 2015;37:1\u20136.","journal-title":"Egypt Rheumatologist"},{"key":"477_CR50","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00774-013-0434-0","volume":"31","author":"Z Zeng","year":"2013","unstructured":"Zeng Z, Zhang C, Chen J. Lentivirus-mediated RNA interference of DC-STAMP expression inhibits the fusion and resorptive activity of human osteoclasts. J Bone Miner Metab. 2013;31:409\u201316.","journal-title":"J Bone Miner Metab"},{"key":"477_CR51","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1126\/science.7939685","volume":"266","author":"AE Grigoriadis","year":"1994","unstructured":"Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 1994;266:443\u20138.","journal-title":"Science"},{"key":"477_CR52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","volume":"12","author":"T Wada","year":"2006","unstructured":"Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12:17\u201325.","journal-title":"Trends Mol Med"},{"key":"477_CR53","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1111\/j.1749-6632.2011.06373.x","volume":"1240","author":"T Nakashima","year":"2011","unstructured":"Nakashima T, Takayanagi H. New regulation mechanisms of osteoclast differentiation. Ann N Y Acad Sci. 2011;1240:E13\u20138.","journal-title":"Ann N Y Acad Sci"},{"key":"477_CR54","doi-asserted-by":"crossref","first-page":"706","DOI":"10.14348\/molcells.2017.0225","volume":"40","author":"JH Park","year":"2017","unstructured":"Park JH, Lee NK, Lee SY. Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol Cells. 2017;40:706\u201313.","journal-title":"Mol Cells"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-0477-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-0477-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-0477-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T04:23:06Z","timestamp":1723350186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-0477-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["477"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-0477-4","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,4]]},"assertion":[{"value":"13 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}